AnalyzeDirect Takahiro Ishizaka et al. Eribulin mesylate induces bone mass loss by promoting osteoclastic bone resorption in mice Bone Reports.
Publication Date
May 30, 2023
How Analyze was Used
“…the structural indices were computed using Analyze 14.0 software (AnalyzeDirect, Overland Park, KS). The region of interest was set at 200–1200 μm, distal to the proximal growth plate of the tibia.”
Keywords
Cancer treatment-induced bone loss, Eribulin mesylate, Osteoclast, Bisphosphonate, RANKL, Osteoprotegerin
Author Affiliation(s)
Keio University School of Medicine, Tokyo, Japan
